SAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage...
Vous n'êtes pas connecté
) Filed Pursuant to Rule 424(b)(3) Registration No. 333-289953 PROSPECTUS 1,592,135 Shares of Common Stock This prospectus relates to the offer and resale by the selling stockholders named in this prospectus (collectively, the "Selling Stockholders") of up to 1,592,135 shares of common stock, par value $0.0001 per share, of Tivic Health Systems, Inc. (the "Company," "we," "our," or "us"), consisting of (i) up to 1,352,395 shares of common stock issuable upon conversion of shares of our Series B Non-Voting Convertible Preferred Stock ("Series B Preferred") issued to Helena Global Investment Opportunities 1 Ltd. ("Helena")...
SAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage...
SAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage...
) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 2) Tender Offer Statement Pursuant to Section...
) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 2) Tender Offer Statement Pursuant to Section...
) FREE WRITING PROSPECTUS Filed Pursuant to Rule 433 Registration Statement Nos. 333-268718 and 333-268718-01 Dated September 11, 2025 Contingent...
) FREE WRITING PROSPECTUS Filed Pursuant to Rule 433 Registration Statement Nos. 333-268718 and 333-268718-01 Dated September 11, 2025 Contingent...
) FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to...
) FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to...
) Pricing Supplement (To Prospectus dated December 30, 2022 and Series P MTN Prospectus Supplement dated December 30, 2022) September 17, 2025 Filed...
) Pricing Supplement (To Prospectus dated December 30, 2022 and Series P MTN Prospectus Supplement dated December 30, 2022) September 17, 2025 Filed...